PPP2CA

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, PPP2CA Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PPP2CA data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher PPP2CA Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PPP2CA expression acts as an unfavorable survival marker.

BRCA, UCEC, and LIHC are the cancer types where PPP2CA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
BRCADFSMedianAll0.4180.903<.00112view →
UCECDFSMedianIV0.2060.704.0336view →
LIHCOSMedianAll0.0980.774.0016view →
Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PPP2CA–BRCA (DFS)

Kaplan–Meier survival curve for PPP2CA mutant vs wild-type samples in BRCA.

Open the BRCA breakdown →

Exploration